RITSUKO KOMAKI to Radiation-Protective Agents
This is a "connection" page, showing publications RITSUKO KOMAKI has written about Radiation-Protective Agents.
Connection Strength
0.967
-
What should the optimal timing be for amifostine administration relative to radiation and chemotherapy? J Clin Oncol. 2005 Oct 01; 23(28):7232-3; author reply 7233-5.
Score: 0.246
-
Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy. Semin Oncol. 2005 Apr; 32(2 Suppl 3):S92-8.
Score: 0.237
-
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1369-77.
Score: 0.222
-
Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. J Clin Oncol. 2011 Jun 20; 29(18):2590-7.
Score: 0.091
-
Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis. Int J Radiat Oncol Biol Phys. 2007 May 01; 68(1):111-8.
Score: 0.067
-
Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol. 2005 Apr 01; 23(10):2145-54.
Score: 0.059
-
Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. Int J Radiat Oncol Biol Phys. 2008 Dec 01; 72(5):1378-84.
Score: 0.018
-
Heterogeneous planning for homogeneous protocols. Med Dosim. 2004; 29(2):80-4.
Score: 0.014
-
The relationship between local dose and loss of function for irradiated lung. Int J Radiat Oncol Biol Phys. 2003 May 01; 56(1):106-13.
Score: 0.013